351 related articles for article (PubMed ID: 27026677)
1. Clinical Trials of Antiangiogenesis Therapy in Recurrent/Persistent and Metastatic Cervical Cancer.
Alldredge JK; Tewari KS
Oncologist; 2016 May; 21(5):576-85. PubMed ID: 27026677
[TBL] [Abstract][Full Text] [Related]
2. Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology.
Eskander RN; Tewari KS
Future Oncol; 2015; 11(6):909-22. PubMed ID: 25760973
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab for the treatment of cervical cancer.
Bizzarri N; Ghirardi V; Alessandri F; Venturini PL; Valenzano Menada M; Rundle S; Leone Roberti Maggiore U; Ferrero S
Expert Opin Biol Ther; 2016; 16(3):407-19. PubMed ID: 26796332
[TBL] [Abstract][Full Text] [Related]
4. Integration of bevacizumab with chemotherapy doublets for advanced cervical cancer.
Krill LS; Tewari KS
Expert Opin Pharmacother; 2015 Apr; 16(5):675-83. PubMed ID: 25643984
[TBL] [Abstract][Full Text] [Related]
5. Changing paradigms in the systemic treatment of advanced cervical cancer.
Pfaendler KS; Tewari KS
Am J Obstet Gynecol; 2016 Jan; 214(1):22-30. PubMed ID: 26212178
[TBL] [Abstract][Full Text] [Related]
6. Targeted Agents in Cervical Cancer: Beyond Bevacizumab.
Marquina G; Manzano A; Casado A
Curr Oncol Rep; 2018 Apr; 20(5):40. PubMed ID: 29611060
[TBL] [Abstract][Full Text] [Related]
7. Exploring the therapeutic rationale for angiogenesis blockade in cervical cancer.
Krill LS; Tewari KS
Clin Ther; 2015 Jan; 37(1):9-19. PubMed ID: 25592088
[TBL] [Abstract][Full Text] [Related]
8. [Not Available].
Kurtz JE; D'Hondt V; Lécuru F; Lhommé C
Bull Cancer; 2017 May; 104 Suppl 1():S39-S42. PubMed ID: 28625314
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab in Cervical Cancer: 5 Years After.
Pfaendler KS; Liu MC; Tewari KS
Cancer J; 2018; 24(4):187-192. PubMed ID: 30119082
[TBL] [Abstract][Full Text] [Related]
10. bevacizumab (Avastin°) in persistent, recurrent or metastatic cervical cancer: Prolongs survival by a few months, but highly toxic.
Prescrire Int; 2016 Oct; 25(175):233. PubMed ID: 30645824
[TBL] [Abstract][Full Text] [Related]
11. Anti-angiogenesis agents in metastatic or recurrent cervical cancer.
Monk BJ; Willmott LJ; Sumner DA
Gynecol Oncol; 2010 Feb; 116(2):181-6. PubMed ID: 19861227
[TBL] [Abstract][Full Text] [Related]
12. The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer.
Minion LE; Tewari KS
Expert Rev Anticancer Ther; 2017 Mar; 17(3):191-198. PubMed ID: 27748633
[TBL] [Abstract][Full Text] [Related]
13. [Targeted therapy in locally and metastatic recurrent cervical cancers].
Geiss R; De La Motte Rouge T; Dubot C; Leary A; Lhommé C; Pautier P; Scholl S; Rodrigues MJ
Bull Cancer; 2014; 101(7-8):748-55. PubMed ID: 25091657
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic management of advanced cervical cancer: antiangiogenesis therapy and immunotherapeutic considerations.
Longoria TC; Tewari KS
Drugs; 2015 Nov; 75(16):1853-65. PubMed ID: 26474780
[TBL] [Abstract][Full Text] [Related]
15. Angiogenesis and antiangiogenic therapy of colon cancer liver metastasis.
Stoeltzing O; Liu W; Reinmuth N; Parikh A; Ahmad SA; Jung YD; Fan F; Ellis LM
Ann Surg Oncol; 2003 Aug; 10(7):722-33. PubMed ID: 12900362
[TBL] [Abstract][Full Text] [Related]
16. The combination of antiangiogenic and cytotoxic agents in the treatment of prostate cancer.
Retter AS; Figg WD; Dahut WL
Clin Prostate Cancer; 2003 Dec; 2(3):153-9. PubMed ID: 15040858
[TBL] [Abstract][Full Text] [Related]
17. Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer.
Rosen VM; Guerra I; McCormack M; Nogueira-Rodrigues A; Sasse A; Munk VC; Shang A
Int J Gynecol Cancer; 2017 Jul; 27(6):1237-1246. PubMed ID: 28448304
[TBL] [Abstract][Full Text] [Related]
18. Clinical trials of antiangiogenic agents.
Twardowski P; Gradishar WJ
Curr Opin Oncol; 1997 Nov; 9(6):584-9. PubMed ID: 9370081
[TBL] [Abstract][Full Text] [Related]
19. TNP-470: an angiogenesis inhibitor in clinical development for cancer.
Kruger EA; Figg WD
Expert Opin Investig Drugs; 2000 Jun; 9(6):1383-96. PubMed ID: 11060750
[TBL] [Abstract][Full Text] [Related]
20. Beyond Chemotherapy: An Overview and Review of Targeted Therapy in Cervical Cancer.
Crafton SM; Salani R
Clin Ther; 2016 Mar; 38(3):449-58. PubMed ID: 26926322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
